{
}
UBS has downgraded Novartis to Neutral from Buy, citing concerns over patent expirations and a limited pipeline, with EBIT growth expected to decline significantly in 2025. In contrast, Roche and AstraZeneca received upgrades to Buy, driven by strong pipeline prospects and revenue growth potential, with Roche's price target raised to CHF 338 and AstraZeneca's to £142.
AstraZeneca has received an upgrade to a "buy" rating from UBS, as reported by Cercle Finance. BOURSORAMA, acting solely as a distribution channel, emphasizes that it has not influenced the analysis, which is provided for informational purposes only and carries no contractual value. The institution maintains a conflict of interest management policy to ensure objectivity in its investment recommendations.
UBS has upgraded AstraZeneca's stock rating from Neutral to Buy, increasing the target price from 11,500 pence to 14,200 pence, indicating a 22% upside potential. For the full year, AstraZeneca reported total sales of $54 billion, an 18% increase, with EPS of $4.54. The company anticipates a high single-digit percentage rise in total sales and a low double-digit percentage increase in core EPS for 2025.
AstraZeneca has been upgraded to a Buy rating from Neutral by UBS, signaling a positive shift in the investment outlook for the company. This upgrade reflects increased confidence in AstraZeneca's performance and potential growth in the market.
UBS has downgraded Novartis from "Buy" to "Neutral," significantly lowering its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's challenges, including numerous patent expiries and a lack of promising developments in the research pipeline, predicting underperformance through 2025. Novartis shares fell by 1.35% to CHF 96.48 following the announcement.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of promising developments in its research pipeline, favoring AstraZeneca as a buy instead.
UBS has upgraded AstraZeneca from "Neutral" to "Buy," reflecting increased confidence in the company's prospects. The bank has also raised its target price for the stock from 11,500 to 14,200 pence, signaling a positive outlook for investors.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of significant new developments in the research pipeline for 2025, favoring AstraZeneca as a buy instead.
UBS has upgraded AstraZeneca from "Neutral" to "Buy," raising its price target from 11,500 to 14,200 pence. Analyst Matthew Weston highlighted the company's significant pipeline potential, projecting an additional USD 17.6 billion in sales by 2030, contingent on successful trial outcomes for seven key drugs in 2025.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of promising developments in its research pipeline for 2025, favoring AstraZeneca as a buy instead.
AstraZeneca PLC
Companies
| Symbol | AZN |
| Name | AstraZeneca PLC |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | United Kingdom |
| State | |
| City | Cambridge |
| Zipcode | CB2 0AA |
| Website | http://www.astrazeneca.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs downgrades novartis while upgrading roche and astrazeneca ratings
British Pound Sterling
Swiss Franc
AstraZeneca PLC
Novartis AG
Hoffmann-La Roche AG
GBR
CHE
Show more
13:01 13.02.2025
ubs upgrades astrazeneca shares to buy rating
12:46 13.02.2025
ubs upgrades astrazeneca to buy with significant target price increase
12:46 13.02.2025
AstraZeneca receives buy rating upgrade from UBS analysts
10:45 13.02.2025
Novartis shares decline as UBS downgrades rating and price target
10:28 13.02.2025
UBS downgrades Novartis to neutral amid patent expiry concerns
09:05 13.02.2025
ubs upgrades astrazeneca to buy raises target price significantly
08:16 13.02.2025
ubs downgrades novartis to neutral lowers price target to 104 francs
08:05 13.02.2025
UBS upgrades AstraZeneca to buy with target raised to 14200 pence
08:05 13.02.2025
ubs downgrades novartis to neutral lowers price target to 104 francs
08:05 13.02.2025
Trending
Subcategory
Corporate News
Industry Trends
Startups & Entrepreneurship
Retail and Consumer Goods
Supply Chain Management
Global Trade Developments
Industry Mergers & Acquisitions
Stock Market Updates
Government Economic Policies
Energy Sector Developments
AI Applications
Private Equity Deals
Funding Rounds & Investments
Fintech Startups
CEO Changes
AI Innovations
Emerging Startups
Workplace Trends
Global Financial Events
Central Bank Actions
Countries:
Companies:
Apple Inc.
Google Inc.
Tesla, Inc.
Amazon.com, Inc.
Microsoft Corporation
Tesmec S.p.A.
Alphabet Inc.
OpenAI ERC USD
Walmart Inc.
SWIGGY LIMITED
NVIDIA Corporation
Foxconn Technology Co., Ltd.
Hollywood Bowl Group PLC
NASDAQ Composite
Wise plc
Mastercard Inc
Mistral 1
TENCENT
Fast Retailing Co., Ltd.
Nippon Steel Corp
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
British Pound Sterling
Japanese Yen
United Arab Emirates Dirham
Vietnamese Đồng
New Zealand Dollar
Saudi Riyal
Thai Baht
Australian Dollar
Indonesian Rupiah
South Korean Won
Singapore Dollar
Omani Rial
Bahraini Dinar
Qatari Riyal
Algerian Dinar
Egyptian Pound
People: